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and Venture Groups Adapt to Challenging TimesSeveral times a week, Markus Frank,
Assistant Professor of Pediatrics at
Harvard Medical School, meets with
scientists from Pfizer, with whom he is
collaborating. Their mutual goal, which
joins Frank and a postdoc with Pfizer
antibody engineers, toxicologists, and
other skilled hands, is to further develop
a strategy for targeting stem cells in
malignant melanoma that Frank has
worked on for 6 years. There’s no need
to commute to the pharmaceutical
giant’s R&D facilities or connect through
Skype. Face-to-face meetings can
even happen spur-of-the-moment, since
Pfizer’s Boston-based Center for Thera-
peutic Innovation (CTI) is directly across
Longwood Avenue from Frank’s lab.
Recognizing the pressing need to
accelerate the job of translating biologic
candidates into drugs, Pfizer began its
global CTI program in 2010, and since
then collaborations with 21 academic
centers have sprung up. For Frank,
who applied through Boston Children’s
Hospital, the partnership is manna
from heaven, for it has allowed Frank to
avoid the traditional start-up model:
a fledgling company seeded by venture
capital or an angel investor. As long as
milestones are met, Pfizer’s support will
continue through a phase 1 proof of
concept in human clinical trials, going
beyond what venture capital typically
covers.
‘‘This way, there’s more consistency
and predictability; the work will stay in
the hands of the original collaborative
arrangement,’’ said Frank. According to
Pfizer officials, the ownership of intellec-
tual property and candidate drugs is
shared evenly between universities and
Pfizer.
Gary Firestein, Dean of Translational
Medicine at the University of California,
San Diego (UCSD) School of Medicine,
is similarly enthusiastic about the UCSD-
Pfizer CTI, which he heads. ‘‘I view it as
essentially prepackaged venture capital,’’
he said. ‘‘Here’s a mechanism for
commercializing an invention that could
potentially bypassmany of the headaches
of starting your own company, like trying12 Cell Stem Cell 12, January 3, 2013 ª2013to find series A money, series B money,
and so on. It frees a scientist up to do
the work he or she wants to do.’’
The estimated value of Pfizer’s 5 year
agreement with UCSD is roughly $50
million.
‘‘Academia will do what it does best,
which is innovate and identify novel
targets, and Pfizer will do what it does
best, which is develop the reagents that
eventually become the drugs,’’ Firestein
noted.
On September 18, 2012, Johnson &
Johnson announced that it, too, will
create innovation centers in known hot-
spots for the life sciences: California
(covering San Francisco and San Diego),
the greater Boston area, London, and
still-to-be-announced locations in China.
‘‘What we want to do is capture more
value by moving earlier in the innovation
chain,’’ said Patrick Verheyen, head of
the London innovation center. ‘‘We want
to be close, very close, to where innova-
tion is happening for the sake of interact-
ingwith that community,’’ and for the sake
of promoting a healthy pipeline of early-
stage assays. Johnson & Johnson plans
to send 15 to 25 scientists to each center,
including scientific experts and a transac-
tional team.
The growing trend among drug compa-
nies to reach deeper and earlier into
academic institutions than they once
did is indicative of shifting ground
between academia, drug, and venture
partners. With traditional bioscience
venture capital (in contrast to pharma
venture capital) having shrunk in recent
years, and with government support
down, diverse funding tactics to bridge
the costly research-to-clinic stretch
known as the Valley of Death are on the
rise.
‘‘Interesting relationships are popping
up,’’ said Leonard Zon, Grousbeck
Professor of Pediatric Medicine at
Harvard Medical School, who noted that
another factor pulling academia and
industry closer together ‘‘is that more
and more academic researchers are
becoming translational investigators. In
the stem cell field, there’s a lot drivingElsevier Inc.them to do high-throughput screening,
and that opens the door for drug
discovery.’’
Data from the 2012 Pricewaterhouse
Coopers/National Venture Capital Associ-
ation MoneyTree Report, released in
August, reveals that in Q2 of 2012,
venture dollars invested in life science
companies fell 39% from the prior year,
while the number of new ventures for
that quarter fell to 14, the fewest since
the 1990s. Nevertheless, venture invest-
ment in some regions remains supremely
healthy, such as in Massachusetts, where
it reached an all-time high in 2011 of
$1.071 billion, according to the same
report.
As for diminishing federal support,
some analysts see that trend continuing
indefinitely on account of baby boomers
retiring and paying less in taxes.Washing-
ton nevertheless appears to grasp that
the translational pipeline needs help.
In December 2011, the NIH established
the National Center for Advancing
Translational Sciences (NCATS) to spur
new public-private partnerships and to
confront and solve pipeline bottlenecks.
In addition, SBIR and STTR grants
(Small Business Innovation Research
and Technology Transfer programs,
respectively) were renewed for another
6 years. Monies for both programs,
set aside by federal departments, have
been a boon for start-ups and kindling
partnerships.
Given the financial pressures, all the
players ‘‘have had to get more innovative
about how they structure partnerships,’’
said Todd Sherer, President of the
Association of University Technology
Managers (AUTM) and Executive Director
of Emory University’s Office of Tech-
nology Transfer. ‘‘Many of the models
we’re seeing have been done in the
past, but not necessarily pursued whole-
sale by everyone in the industry. What’s
clear is that there’s no one particular
model—wemay never have one particular
model!’’
Currently, partnerships ‘‘run the
gamut,’’ Sherer observed. ‘‘At one end
of the spectrum you have multidollar
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cluster of expertise at an institution, like
Pfizer’s CTIs, or the program between
AstraZeneca and Penn,’’ which is focused
on generating new drug compounds
for Alzheimer’s disease. ‘‘At the other
end, there are programs like Eli Lilly’s
OIDD program,’’ which encompasses
Lilly’s popular PD2 initiative and its
free offer to universities to screen mole-
cules that might lead to therapies for
Alzheimer’s disease, cancer, diabetes,
or osteoporosis.
Newly organized efforts on campuses
to identify entrepreneurs and help guide
and fund their inventions are thriving.
Witness, for example, the Emory Institute
for Drug Discovery, or Harvard’s The
Experiment Fund, each established to
bolster entrepreneurs with seed capital
and/or scientific and corporate exper-
tise. Technologies looking for a funding
home abound. The AUTM Global Tech-
nology Portal (GTP), a website launched
earlier this year where academics
post their technologies and companies
review them, already lists over 22,000
technologies, the majority rooted in
bioscience.
Speaking from the vantage point of
tech transfer, Sherer thinks that in
the future, ‘‘we won’t just be in the busi-
ness of selling individual technologiesanymore. our institutions will need to
think more in terms of selling assets—
a research expertise in neuroscience, for
instance, or a high-throughput screening
center. We may have to think about
assets in a bigger way, because you’ll
need to attract a partnership with a
company as opposed to just out-licensing
technology.’’
Where does all of this leave venture
capital groups? ‘‘They will tell you, it’s
a new game,’’ said Zon.
Generally, traditional venture capital
groups are investing in ventures at later
stages, improving investors’ chances of
seeing a return. On the other hand,
some are buffering the risk of going into
early-stage ventures by partnering with
a drug company. This year, for instance,
Sanofi together with the venture firms
Third Rock and Greylock poured $125
million into Warp Drive Bio, a startup in
Cambridge, MA.
‘‘Third Rock was going to start the
company on its own,’’ recounted Gregory
Verdine, a chemistry professor at Harvard
and a venture partner at Third Rock who
was the mover and shaker behind the
company’s focus on converting genomic
sequences into drugs. ‘‘But Sanofi got
so excited about the science, they said,
‘We want to establish and build the
company together.’ What’s important isCell Stem Cellthat they allowed Warp Drive to be a fully
independent entity and are delighted to
be equity shareholders in a company
that shows every indication of being spec-
tacularly successful.’’
Something else that’s different about
this deal, noted Zon, is that once upon
a time, ‘‘venture partners would not have
allowed this partnering, because they
would have wanted full control.’’ Thus,
traditional venture capital firms are also
trying to reinvent themselves, especially
given that investors in bioscience are
harder to find these days.
Concurrently, drug company venture
capital funds are also changing their
game plan. ‘‘Pharma are realizing they
need to step in and play a role in making
sure that the pipeline of innovation is
still there, and one way of doing that is
for their corporate venture arms to invest
at a much earlier stage,’’ said Alan Crane,
a general partner at Polaris Venture
Partners. Moreover, there’s evidence
that when corporate venture firms back
early-stage therapeutics companies,
these companies ‘‘are more likely than
other venture-backed companies to
enter into licensing or collaborative deals,
and be acquired or complete an initial
public offering,’’ reported the Burrill
Report in June, citing data from an anal-
ysis of therapeutic venture investments
made between 2000 and 2011.
Furthermore, in the spirit of these
anything-goes times, traditional and
pharma venture capital funds partner-
ships are flourishing. Polaris, for instance,
has deals in the works with a dozen or
more pharma venture arms. Because of
these liaisons, said Crane, ‘‘our compa-
nies have greater access to pharma
expertise, increased opportunities to
form strategic partnerships that can help
leverage venture dollars and fund the
expensive development of products, and
better chances of valuable company
acquisitions.’’
‘‘It’s fascinating to think about where
we’ll be in 5–10 years,’’ said Sherer,
‘‘because right now we’re in the process
of reformulating the model, or models,
and there’s no clear indication yet of
how successful this will be for increasing
the number of new drug approvals. The
point is, if the remodeling works the way
it’s supposed to, in a few years we theo-
retically will be heading up later-stage
technologies to spin out of universities,12, January 3, 2013 ª2013 Elsevier Inc. 13
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have to rely on the venture capital industry
to back up into the Valley of Death as far14 Cell Stem Cell 12, January 3, 2013 ª2013as they used to, because academia is
going to continue to push them further
into the valley.’’Elsevier Inc.ACKNOWLEDGMENTS
A.P. is a shareholder of Pfizer.Ann Parson*
South Dartmouth, MA, USA
*Correspondence: parson-a@verizon.net
http://dx.doi.org/10.1016/j.stem.2012.
11.020
